GlassScriptPhysician profile
Venitius D Nunez
NPI 1407973035
$15,663.71
in general payments reported to CMS, 2019-2025
22 companies · $3,190 in 2025
The $3,190 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,089 · 2020: $1,867 · 2021: $2,868 · 2022: $2,304 · 2023: $1,264 · 2024: $2,081 · 2025: $3,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,331 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,331.21 |
| Education | $203.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,447.35 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $1,962.98 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $1,703.32 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,614.17 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,502.21 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,469.76 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $1,002.29 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $968.48 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $954.97 | 2019-2025 | Invega, Invega Sustenna |
| Lundbeck LLC | $534.27 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $364.88 | 2024-2025 | Cobenfy |
| Allergan, INC. | $258.05 | 2019-2020 | |
| Noven Therapeutics, LLC | $245.45 | 2020-2022 | |
| Indivior INC. | $163.73 | 2020-2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $148.97 | 2019-2023 | Trintellix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.34 | 2019-2022 | |
| Axsome Therapeutics, INC. | $72.96 | 2025 | Auvelity |
| Almatica Pharma LLC | $66.18 | 2021-2022 | |
| Brainsway USA INC | $33.41 | 2020 | |
| Janssen Scientific Affairs, LLC | $20.50 | 2024 | Invega Sustenna |
| Luye Pharma (USA) LTD. | $16.68 | 2025 | Erzofri Extended-Release |
| Noven Pharmaceuticals, INC. | $13.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venitius Nunez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.